NDA 021880 · Bristol Myers Squibb
Revlimid
Lenalidomide · Oral · Thalidomide Analog
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Dec 27, 2005
Approved uses
9
Original approval plus efficacy supplements
Registered trials
1,232
199 Phase 3, 149 recruiting
FAERS reports
425,916
271,846 serious, 54,138 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID ® treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment [see Warnings and Precautions ( 5.1 ), and Medication Guide ( 17 )]. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program,...
What it is approved for
From the label in effect Mar 24, 2023.
REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular...
Mechanism: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 2019 Supplement 57 · Efficacy · priority review OrphanLabelLetter
- Sep 15, 2017 Supplement 51 · Efficacy · priority review OrphanLabelLetter
- Feb 22, 2017 Supplement 49 · Efficacy · priority review OrphanLabelLetter
- Feb 17, 2015 Supplement 41 · Efficacy OrphanLabelLetter
- Jun 5, 2013 Supplement 34 · Efficacy · priority review OrphanLabelLetter
- Dec 21, 2011 Supplement 23 · Efficacy LetterLabel
- Oct 12, 2010 Supplement 18 · Efficacy LabelLetter
- Jun 29, 2006 Supplement 1 · Efficacy · priority review LabelLetter
- Dec 27, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelREMSReview
6 products under this application
- REVLIMID · LENALIDOMIDE 2.5MG · CAPSULE, ORAL · Prescription · TE AB
- REVLIMID · LENALIDOMIDE 15MG · CAPSULE, ORAL · Prescription · TE AB
- REVLIMID · LENALIDOMIDE 5MG · CAPSULE, ORAL · Prescription · TE AB
- REVLIMID · LENALIDOMIDE 20MG · CAPSULE, ORAL · Prescription · TE AB
- REVLIMID · LENALIDOMIDE 25MG · CAPSULE, ORAL · Prescription · TE AB
- REVLIMID · LENALIDOMIDE 10MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lenalidomide" as an intervention, any sponsor and status, largest first.
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple MyelomaPivotal-lookingCompleted
Celgene CorporationBristol Myers Squibb (BMY)
NCT00179647 · 1,913 participants · Start Sep 2005 · Primary completion Dec 2008
Drug: lenalidomide; dexamethasone · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Berkeley, California; La Jolla, California · 69 sites in all
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT00689936 · 1,623 participants · Start Aug 21, 2008 · Primary completion Jul 14, 2016
Drug: Lenalidomide and low-dose dexamethasone; Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles and 1 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 288 sites in all
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationPivotal-lookingActive, not recruiting
European Myeloma Network B.V.Research network
NCT05243797 · 1,594 participants (planned) · Start Sep 8, 2022 · Primary completion Apr 2028
Drug: Teclistamab; Lenalidomide · For: Multiple Myeloma
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 201 sites in all
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingCompleted
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT01208766 · 1,503 participants · Start Jan 2011 · Primary completion Dec 2020
Drug: Bortezomib, Melphalan, Prednisone (VMP); 1 or 2 cycle(s) HDM (High Dose Melphalan) and 1 more · For: Multiple Myeloma
Sites: Brisbane, Australia; Canberra, Australia; Melbourne, Australia · 208 sites in all
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05827016 · 1,230 participants · Start Jun 22, 2023 · Primary completion Mar 15, 2029
Drug: Iberdomide; Lenalidomide · For: Multiple Myeloma
Sites: Aurora, Colorado; Jacksonville, Florida; Tampa, Florida · 269 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea31,968
- fatigue27,107
- death26,885
- off label use19,177
- pneumonia19,040
- rash18,551
- plasma cell myeloma17,292
- neuropathy peripheral12,297
- white blood cell count decreased12,018
- constipation11,201
- nausea10,998
- asthenia10,240
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 15 |
| 2006 | 820 |
| 2007 | 1,497 |
| 2008 | 3,609 |
| 2009 | 2,897 |
| 2010 | 3,897 |
| 2011 | 6,340 |
| 2012 | 11,712 |
| 2013 | 10,519 |
| 2014 | 9,108 |
| 2015 | 34,550 |
| 2016 | 25,534 |
| 2017 | 28,602 |
| 2018 | 26,535 |
| 2019 | 30,129 |
| 2020 | 33,935 |
| 2021 | 52,556 |
| 2022 | 43,269 |
| 2023 | 29,356 |
| 2024 | 30,439 |
| 2025 | 23,903 |
| 2026 | 16,693 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Revlimid (Lenalidomide)
2024 spending
$4.18B
Beneficiaries
38,868
239,843 claims
Per beneficiary
$107,531
$854.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,356,050,275 |
| 2021 | $5,893,547,689 |
| 2022 | $5,935,051,092 |
| 2023 | $3,859,804,789 |
| 2024 | $4,179,511,486 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, et al. · Nat Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, et al. · J Clin Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.